Anesthesia,Postoperative Analgesia, Enhanced Recovery After Surgery (ERAS)
Conditions
Interventions
Trial group:Patients in the experimental group received perincisional infiltration of liposomal bupivacaine (manufacturer: Jiangsu Hengrui, drug registration number: YBH13632022). The formulation cons
Control Group:The blank control group did not receive perineural infiltration injection of bupivacaine liposomes.
Sponsors
Department of Anesthesiology, Suzhou University Affiliated Fourth Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: This study intends to enroll patients aged 18–75 years, classified as ASA II–III, who are scheduled to undergo laparoscopic colon and/or rectal resection at the Fourth Affiliated Hospital of Soochow University and the First Affiliated Hospital of Soochow University.
Exclusion criteria
Exclusion criteria: The exclusion criteria include: impaired cardiovascular function, abnormal liver or kidney function, coagulation disorders, infection at the puncture site, mental or language impairments, pregnancy, chronic opioid use, allergy to bupivacaine, intraoperative conversion to open surgery, and patients whose postoperative pain assessment is affected by stoma placement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum pain score at 48 hours postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative pain scores at rest and during activity at 6 hours.;Postoperative pain scores at rest and during activity at 12 hours.;Postoperative pain scores at rest and during activity at 24 hours.;Postoperative pain scores at rest and during activity at 48 hours.;Postoperative pain scores at rest and during activity at 72 hours.;Total consumption of patient-controlled analgesia (PCA) postoperatively;Quality of Recovery (QoR) Score; | — |
Countries
China
Contacts
Public ContactHou Yongheng
Suzhou University Affiliated Fourth Hospital
Outcome results
None listed